Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17‐Mediated Pro‐Inflammatory Axis to Mitigate EAE
European Journal of Immunology · 2026-11 · 56 (11)
DOI: 10.1002/eji.70311 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 16.11.2026. Verfasst von Jie Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of the Ministry of Education, Orthopaedic Department of Tongji Hospital, Schoo…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Artemisinins, Th17 Cells, Th1 Cells. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a central nervous system (CNS)‐specific chronic disorder, characterized by T cell‐mediated demyelination and neuroinflammation. Dihydroartemisinin, a semisynthetic artemisinin derivative, has been reported as a potential MS treatment for its immunomodulatory activity. This work investigated dihydroartemisinin acetal dimer (DHAAD), a novel dihydroartemisinin derivative, for MS therapy and explored possible mechanistic insights. A library of 14 small‐molecule compounds was screened through in vitro Th1/Th17 differentiation assays. Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, was induced in mice with the MOG 35 − 55 peptide. The compound identified through screening was orally administered to mice at various doses. Its therapeutic effects at the tissue and cellular levels were assessed using histopathological analysis and flow cytometry, respectively, while the effects on cytokine levels and signature gene expression were evaluated through enzyme‐linked immunosorbent assay and quantitative polymerase chain reaction, respectively. DHAAD was identified as effectively inhibiting Th1/Th17 cell differentiation. DHAAD treatment mitigated EAE manifestations in mice (reduced clinical scores, leukocyte infiltration, and CNS demyelination) and suppressed Th1/Th17 cell populations in both CNS and peripheral compartments, concurrently reducing IFN‐γ and IL‐17A secretion. Upon MOG 35 − 55 re‐stimulation, splenocytes and lymph node cells from treated mice also exhibited decreased IFN‐γ and IL‐17A production. Furthermore, DHAAD administration downregulated the genes driving Th1/Th17 cell differentiation and those executing their pro‐inflammatory functions. DHAAD alleviates EAE symptoms by suppressing pro‐inflammatory Th1/Th17 differentiation pathways through its immunosuppressive effects in the CNS and peripheral sites, thereby ameliorating inflammation and revealing its application potential in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of the Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
- CAS Key Laboratory For Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
ORCID-Profile: Changsheng Du
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, J., Wan, G., Luo, J., Jiang, X., & Du, C. (2026). Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17‐Mediated Pro‐Inflammatory Axis to Mitigate EAE. European Journal of Immunology, 56(11). https://doi.org/10.1002/eji.70311
Vancouver
Lv J, Wan G, Luo J, Jiang X, Du C. Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17‐Mediated Pro‐Inflammatory Axis to Mitigate EAE. European Journal of Immunology. 2026;56(11). doi:10.1002/eji.70311
BibTeX
@article{Lv2026,
author = {Lv, Jie and Wan, Gen and Luo, Jing and Jiang, Xiangrui and Du, Changsheng},
title = {Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17‐Mediated Pro‐Inflammatory Axis to Mitigate EAE},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {11},
doi = {10.1002/eji.70311}
}
EUVIMED